Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Targeted-Capture Sequencing Approach to V(D)J Rearrangement, Immunoglobulin (Ig) Translocation and Mutation Detection in Multiple Myeloma (MM): Potential Applications in Minimal Residual Disease (MRD) Analysis and Comparison to Multiparameter Flow Cytometry (MFC) in the Myeloma Canada Research Network (MCRN) 001 Study with Intravenous Busulfan and Melphalan (BuMel) Conditioning Followed By Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2017) 130 (Supplement 1): 3057.

https://doi.org/10.1182/blood.V130.Suppl_1.3057.3057

Published: 2017

Journal Articles

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

Blood (2017) 130 (Supplement 1): 1811.

https://doi.org/10.1182/blood.V130.Suppl_1.1811.1811

Published: 2017

Journal Articles

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Blood (2017) 130 (Supplement 1): 1888.

https://doi.org/10.1182/blood.V130.Suppl_1.1888.1888

Published: 2017

Journal Articles

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Blood (2017) 130 (Supplement 1): 4533.

https://doi.org/10.1182/blood.V130.Suppl_1.4533.4533

Published: 2017

Journal Articles

Toxicity and Outcomes of Autologous Stem Cell Transplant in Multiple Myeloma Patients with Renal Insufficiency: An Institutional Comparison between Two Eras

Amanda Li, MD BSc, Eshetu G Atenafu, M.Sc., P.Stat, Rosanne St. Bernard, MD MSc, Esther Masih-Khan, PhD, Donna Reece, MD FRCP(C), Norman Anthony Franke, MD, Rodger Tiedemann, MBChB, PhD, Anca Prica, MD FRCP(C), Suzanne Trudel, MD FRCP(C), Vishal Kukreti, MD FRCP(C), Christine I Chen, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 4537.

https://doi.org/10.1182/blood.V130.Suppl_1.4537.4537

Published: 2017

Journal Articles

Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience

Chloe Yang, MD BS, Haiyan Jiang, PhD, Esther Masih-Khan, PhD, Christine I Chen, MD FRCP(C), Anca Prica, MD FRCP(C), Donna Reece, MD FRCP(C), Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD FRCP(C), Vishal Kukreti, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 3462.

https://doi.org/10.1182/blood.V130.Suppl_1.3462.3462

Published: 2017

Journal Articles

Cost Analysis of Stored Autologous Peripheral Blood Stem Cells for a Second Autologous Transplantation in Multiple Myeloma Patients: A Markov Model

Anca Prica, MD, Vinita Dhir, Nuchanan Areethamsirikul, MD, Christine Chen, MD, Donna Reece, MD, Suzanne Trudel, MD, Rodger Tiedemann, MBChB, PhD, Vishal Kukreti, MD

Blood (2016) 128 (22): 1184.

https://doi.org/10.1182/blood.V128.22.1184.1184

Published: 2016

Journal Articles

Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant

Henry Siu Him Chan, MBChB, Madeline Phillips, Sophia Farooki, MD FRCPC, Giovanni Piza Rodriguez, MD, Esther Masih-Khan, PhD, Christine Chen, MD, Vishal Kukreti, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Donna Reece, MD

Blood (2016) 128 (22): 3457.

https://doi.org/10.1182/blood.V128.22.3457.3457

Published: 2016

Journal Articles

Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)

Todd Zimmerman, MD, Noopur S. Raje, Ravi Vij, Donna Reece, MD, Jesus G. Berdeja, MD, Leonor A Stephens, PhD, Kathryn McDonnell, Cara A. Rosenbaum, MD, Jagoda Jasielec, MD, Paul G Richardson, MD, Sandeep Gurbuxani, Jennifer Nam, Erica Severson, Brittany D. Wolfe, MMS, PA-C, Shaun Rosebeck, PhD, Andrew Stefka, Dominik Dytfeld, MD PhD, Kent Griffith, PhD, Andrzej Jakubowiak, MDPhD

Blood (2016) 128 (22): 675.

https://doi.org/10.1182/blood.V128.22.675.675

Published: 2016

Journal Articles

Results of Salvage Autologous Stem Cell Transplantation (ASCT) for Relapsed Multiple Myeloma (MM) in the Era of Novel Agents: Outcome of Patients (Pts) Receiving Prior Bortezomib (BTZ)-Based Therapy

Sara Farshchi Zarabi, MD, Esther Masih-Khan, PhD, Christine Chen, Vishal Kukreti, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Donna Reece, MD

Blood (2016) 128 (22): 5821.

https://doi.org/10.1182/blood.V128.22.5821.5821

Published: 2016

Journal Articles

A Rapid Desensitization Program Is a Viable Therapeutic Option in the Management of Immunomodulating Agent-Related Hypersensitivity Reactions in Patients with Plasma Cell Disorders

Jack T Seki, PharmD, Naoko Sakurai, Phm, MSc, Wallace Lam, BSc, Phm, Vesna Lukaroska, BSc, Phm, Anna Granic, BSc, Phm, Patricia Disperati, MD, Amy Tam, MD, Suzanne Trudel, MD, Donna Reece, MD

Blood (2016) 128 (22): 2411.

https://doi.org/10.1182/blood.V128.22.2411.2411

Published: 2016

Journal Articles

IKZF1/3 Protein Expressions Are Associated with a Better Survival in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide

Maryam Pourabdollah, MD, Mohammad Bahmanyar, MD, Eshetu G Atenafu, MSc, PStat, Donna Reece, MD, Hong Chang, MD PhD

Blood (2016) 128 (22): 4506.

https://doi.org/10.1182/blood.V128.22.4506.4506

Published: 2016

Journal Articles

Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhD MSc, Darrell White, MD, Christopher P. Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin W. Song, MD, Jean Roy, MD, Martha L Louzada, MD, Arleigh McCurdy, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD, Harminder Paul, BSc

Blood (2016) 128 (22): 4632.

https://doi.org/10.1182/blood.V128.22.4632.4632

Published: 2016

Journal Articles

Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting

Julie Cote, MD, Madeline Phillips, Eshetu G Atenafu, MSc, PStat, Esther Masih-Khan, PhD, Donna Reece, MD, Christine Chen, MD, Anca Prica, MD, Rodger Tiedemann, MD PhD, Suzanne Trudel, MD, Vishal Kukreti, MD

Blood (2016) 128 (22): 2137.

https://doi.org/10.1182/blood.V128.22.2137.2137

Published: 2016

Journal Articles

Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study

Blood (2015) 126 (23): 5322.

https://doi.org/10.1182/blood.V126.23.5322.5322

Published: 2015

Journal Articles

Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum Hevylite TMÂ chain (HLC) Normalization

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhDMSc, Darrell White, MD, Christopher P. Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin Song, MD, Jean Roy, MD, Leonard Minuk, MD, Jason Tay, MD MSc, Vishal Kukreti, MD, Suzanne Trudel, MD, Prica Anca, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD, Harminder Paul

Blood (2015) 126 (23): 1982.

https://doi.org/10.1182/blood.V126.23.1982.1982

Published: 2015

Journal Articles

Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023

Jesus San Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Jatin J. Shah, MD, Enrique M. Ocio, MD PhD, Paula Rodriguez-Otero, MD PhD, Donna Reece, MD, Nikhil C. Munshi, MD, David Avigan, MD, Yang Ge, PhD, Arun Balakumaran, MD PhD SM, Patricia Marinello, PharmD, Robert Z. Orlowski, MD PhD, David Siegel, MD PhD

Blood (2015) 126 (23): 505.

https://doi.org/10.1182/blood.V126.23.505.505

Published: 2015

Journal Articles

First Report of the Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide Maintenance: Feasibility of a National Canadian Study Based on Achievement of Minimal Residual Disease (MRD) Negativity

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhD MSc, Christopher P. Venner, MD, Darrell White, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin Song, MD, Jean Roy, MD, Leonard Minuk, MD, Jason Tay, MD MSc, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD

Blood (2014) 124 (21): 3990.

https://doi.org/10.1182/blood.V124.21.3990.3990

Published: 2014

Journal Articles

Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Patients over Age 70.

Carla Borgono, PhD, Young Trieu, MSc, Wei Xu, PhD, Jacob Pendergrast, MD, Donna Reece, MD, Suzanne Trudel, MD, Joseph Mikhael, MD, Vishal Kukreti, MD, Christine I. Chen, MD

Blood (2007) 110 (11): 4952.

https://doi.org/10.1182/blood.V110.11.4952.4952

Published: 2007

Journal Articles

Age under 40 Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplant Despite High Response Rates.

Parneet K. Cheema, MD, Sahar Zadeh, BSc, Donna Reece, MD, Christine I. Chen, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, Joseph R. Mikhael, MD

Blood (2007) 110 (11): 5123.

https://doi.org/10.1182/blood.V110.11.5123.5123

Published: 2007

NARROW

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Toxicity and Outcomes of Autologous Stem Cell Transplant in Multiple Myeloma Patients with Renal Insufficiency: An Institutional Comparison between Two Eras

Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience

Cost Analysis of Stored Autologous Peripheral Blood Stem Cells for a Second Autologous Transplantation in Multiple Myeloma Patients: A Markov Model

Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant

Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)

Results of Salvage Autologous Stem Cell Transplantation (ASCT) for Relapsed Multiple Myeloma (MM) in the Era of Novel Agents: Outcome of Patients (Pts) Receiving Prior Bortezomib (BTZ)-Based Therapy

A Rapid Desensitization Program Is a Viable Therapeutic Option in the Management of Immunomodulating Agent-Related Hypersensitivity Reactions in Patients with Plasma Cell Disorders

IKZF1/3 Protein Expressions Are Associated with a Better Survival in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide

Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments

Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting

Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study

Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023

Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Patients over Age 70.

Age under 40 Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplant Despite High Response Rates.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only